Table 2.
Molecular subtyping and clinical characteristics.
| Variable | Molecular subtyping | |||
|---|---|---|---|---|
| Luminal A | Luminal B | HER2(+) | TNBC | |
| No. of subtyping patients: n (%) | 96 (100) | 37 (100) | 74 (100) | 49 (100) |
| Age: Median [range] | 61 [37-88] | 66 [41-88] | 57 [33-87] | 57 [32-84] |
| TNM stage: n (%) | ||||
| I | 21 (22.1) | 7 (18.9) | 16 (22.2) | 12 (25) |
| II | 46 (48.4) | 24 (64.9) | 33 (45.8) | 18 (37.5) |
| III | 28 (29.5) | 6 (16.2) | 23 (32.0) | 18 (37.5) |
| Lymphatic metastasis: n (%) | ||||
| Negative | 47 (51.6) | 20 (58.8) | 36 (50.7) | 26 (53.1) |
| Positive | 44 (48.4) | 14 (41.2) | 35 (49.3) | 23 (46.9) |
| Prognosis: n (%) | ||||
| Survival | 79 (82.3) | 34 (91.9) | 52 (70.3) | 30 (61.2) |
| Death | 17 (17.7) | 3 (8.1) | 22 (29.7) | 19 (38.8) |
| PTK7 expression | ||||
| IHC score: Mean ± s.d. | 5.06 ± 2.42 | 5.12 ± 2.39 | 6.20 ± 2.41 | 7.46 ± 2.68 |
| Low PTK7 level: n (%) | 36 (37.5) | 13 (35.1) | 20 (27.0) | 6 (12.2) |
| Medium PTK7 level: n (%) | 41 (42.7) | 14 (37.8) | 25 (33.8) | 12 (24.5) |
| High PTK7 level: n (%) | 19 (19.8) | 10 (27.0) | 29 (39.2) | 31 (63.3) |